Vinflunine

Vinflunine

Clinical data
AHFS/Drugs.com	International Drug Names
License data	EU EMA: Javlor
Routes of administration	Intravenous
ATC code	L01CA05 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name methyl (2β,3β,4β,5α,12β,19α)- 4-(acetyloxy)- 15-[(4R,6R,8S)- 4-(1,1-difluoroethyl)- 8-(methoxycarbonyl)- 1,3,4,5,6,7,8,9-octahydro- 2,6-methanoazecino[4,3-b]indol- 8-yl]- 3-hydroxy- 16-methoxy- 1-methyl- 6,7-didehydroaspidospermidine- 3-carboxylate
CAS Number	162652-95-1 Y
PubChem CID	10629256
ChemSpider	8804619 N
UNII	5BF646324K
ChEBI	CHEBI:90241 N
ChEMBL	CHEMBL510329 N
Chemical and physical data
Formula	C45H54F2N4O8
Molar mass	816.92 g/mol
3D model (Jmol)	Interactive image
SMILES CC[C@@]12C=CCN3[C@@H]1[C@]4(CC3)[C@H]([C@]([C@@H]2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)[C@]6(C[C@H]7C[C@H](CN(C7)CC8=C6NC9=CC=CC=C89)C(C)(F)F)C(=O)OC)OC)C
InChI InChI=1S/C45H54F2N4O8/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44/h9-14,19-20,26-27,36-38,48,55H,8,15-18,21-24H2,1-7H3/t26-,27+,36-,37+,38+,42+,43+,44-,45-/m0/s1 N Key:NMDYYWFGPIMTKO-KLCPSUAYSA-N N
NY (what is this?)

Vinflunine (INN, trade name Javlor) is a novel fluorinated Vinca alkaloid undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 - Poitiers University), developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States.

On November 23, 2007, Pierre Fabre and BMS announced that they are terminating their license agreement for the development of vinflunine.

As of 2016^[update] In some countries, vinflunine is the only commercially approved agent for salvage therapy of urothelial carcinoma, (with approval based on the results of a phase III trial), with a reported median OS of about 6 months.

It has undergone a phase III clinical trial for advanced transitional cell carcinoma of the urothelial tract.